The Medicines Company (MDCO) has been upgraded today by the securities research analysts at investment firm Argus which raised The Medicines Company from a “hold” rating to “buy.” Argus did not adjust their price target for ‘MDCO’ which remains fixed at $25 dollars. However, Argus did note that The Medicines Company is benefiting from a patent extension of its anticoagulant Angiomax product. MDCO is up during intraday trading – shares had been on a downtrend after reaching the standing 52-week high of $19.40.
The Medicines Company is slated to release their next earnings report on July 27th, 2011 and the current consensus EPS estimate is expected to be 19 cents. The Medicines Company last reported earnings on April 27th, 2011 and announced EPS of 45 cents with revenue totaling $112.1 million which was up 9.8 % year to year. MDCO is currently trading above its 50 & 200-day moving averages and 2011 is currently an up year for the company.
The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The company has market capitalization of $959,000,000 and 53,386,000 shares outstanding. MDCO has a 52-week high of $19.39 with the low being $7.24 dollars.
